2006 Industry Dynamics: Lessons to Be LearnedDecision ResourcesDecember 21, 2006 35 Pages - SKU: DECR1402582 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
Out-of-Pocket Healthcare 2012
4/3/2012 | published by: Kalorama Information
Despite numerous attempts to reign in costs of healthcare, consumers are increasingly paying for healthcare products and services from their own monies. The costs of health care products and services continue
|
more...
|
$995.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
4/30/2012 | published by: GBI Research
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion Summary GBI Research, the leading business intelligence provider, has released its latest research, “Cytotoxic Therapies Market
|
more...
|
$3,500.00
|
|
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease
|
more...
|
$3,500.00
|
|
Ophthalmic Drugs: World Market Prospects 2012-2022
3/16/2012 | published by: Visiongain
How to find trends and revenue predictions for the ophthalmic drug industry
What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions.
|
more...
|
$2,642.00
|
|
China Pharmaceutical Industry Research and Forecast to 2016
3/1/2012 | published by: AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms of patented drugs, generic drugs, OTC drug and even sub-segments
|
more...
|
$700.00
|
|
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation
2/29/2012 | published by: GlobalData
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation Summary The report is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with
|
more...
|
$500.00
|
Related Markets
Prescription Drugs Reports
- Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Chinese Markets for Hepatitis Drugs
- Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
